• Chief Healthcare ExecutiveChief Healthcare Executive
  • Formulary WatchFormulary Watch
  • Managed Healthcare Executive
  • Medical EconomicsMedical Economics
Managed Healthcare Executive
Managed Healthcare Executive
Resource Centers
View MoreHIVLiver DiseaseSleep DisordersBiosimilarsCovid-19AsthmaEye CareMultiple SclerosisPost-Acute CarePrescription Digital TherapeuticsRespiratory ConditionsSubstance Use DisorderType II Inflammation
Spotlight
A Collaboration That Will Help Payers Recognize the Potential Digital Health Can Bring to PatientsAMCP AnnualAsembia’s 2022 Specialty Pharmacy SummitAMCP NexusThe Improving Patient Access PodcastWet Age-Related Macular Degeneration: Understanding Disease Impact and Refining Treatment ApproachesParadigms in Insulin Use for Type 2 DiabetesPBMI National ConferenceRespiratory ConditionsShort on staff? Efficiency—not hiring—may be the best answerSupporting Better Cancer Care Through Comprehensive Genomic Profiling (CGP)
Business
View MoreBusiness StrategyChronic DiseaseConsumersDrug CostsDrug PipelineFormularyHealth ManagementHealth/Disease StrategyHospitals & ProvidersIndustry AnalysisPharmacyPolitics and PolicyPractice ManagementReimbursementTechnology
News
Media
Expert Interviews
K-Cast
Medical World News
Podcasts
Population Health Perspectives
Conferences
Publications
MHE Publication
Supplements And Featured Publications
Events
Virtual Events
CME/CE
Resources
PBM Leaders
Sponsored
Sponsored Content
Surveys
Subscribe
eNewsletter
Print Subscription
  • Advertise
  • Editorial
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Informations

© 2022 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.

Resource CentersSee All >
  • HIV
  • Liver Disease
  • Sleep Disorders
  • Biosimilars
  • Covid-19
  • Asthma
  • Eye Care
  • Multiple Sclerosis
  • Post-Acute Care
  • Prescription Digital Therapeutics
  • Respiratory Conditions
  • Substance Use Disorder
  • Type II Inflammation
Spotlight
  • A Collaboration That Will Help Payers Recognize the Potential Digital Health Can Bring to Patients
  • AMCP Annual
  • Asembia’s 2022 Specialty Pharmacy Summit
  • AMCP Nexus
  • The Improving Patient Access Podcast
  • Wet Age-Related Macular Degeneration: Understanding Disease Impact and Refining Treatment Approaches
  • Paradigms in Insulin Use for Type 2 Diabetes
  • PBMI National Conference
  • Respiratory Conditions
  • Short on staff? Efficiency—not hiring—may be the best answer
  • Supporting Better Cancer Care Through Comprehensive Genomic Profiling (CGP)
BusinessSee All >
  • Business Strategy
  • Chronic Disease
  • Consumers
  • Drug Costs
  • Drug Pipeline
  • Formulary
  • Health Management
  • Health/Disease Strategy
  • Hospitals & Providers
  • Industry Analysis
  • Pharmacy
  • Politics and Policy
  • Practice Management
  • Reimbursement
  • Technology
  • Advertise
  • Editorial
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Informations
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.

Advances in Biomarker-Driven Therapy for Advanced NSCLC

Paul K. Paik, MD, discusses the spectrum of targeted therapy in non-small cell lung cancer.

EP. 1: Importance of Biomarker Testing in NSCLC

May 20th 2021

Paul K. Paik, MD, reviews the importance of biomarker testing and best practices in testing in patients with non-small cell lung cancer.

EP. 2: Targetable Gene Alterations in NSCLC

May 27th 2021

An expert in non-small cell lung cancer describes targetable gene alterations and how these impact treatment selection.

EP. 3: NSCLC: Targeted Therapy Landscape

June 1st 2021

Paul K. Paik, MD, discusses currently available targeted therapies for patients with NSCLC.

EP. 4: The Role of MET in NSCLC

June 1st 2021

A key opinion leader thoracic oncology reviews the clinical significance of MET exon 14 skipping in NSCLC as well as recent advances in MET-directed therapy.

EP. 5: The VISION Trial

June 1st 2021

An expert in non-small cell lung cancer discusses the key efficacy and safety findings from the VISION trial of tepotinib in patients with NSCLC and MET exon 14 skipping alterations.

EP. 6: Implications of the VISION Trial for Clinical Practice

June 1st 2021

Paul K. Paik, MD, discusses how the results of the VISION trial and the recent FDA approval of tepotinib will impact clinical practice.

EP. 7: Looking Ahead in the Treatment of NSCLC

June 1st 2021

Paul K. Paik, MD, considers the future of MET-directed therapies in non-small cell lung cancer.